Monoclonal antibodies in treatment of multiple sclerosis

P. S. Rommer, A. Dudesek, O. Stüve, U. K. Zettl

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalClinical and Experimental Immunology
Volume175
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Multiple Sclerosis
Monoclonal Antibodies
Relapsing-Remitting Multiple Sclerosis
ocrelizumab
Integrin alpha4
Graft Rejection
Rheumatology
Gastroenterology
Dermatology
Medicine
Clinical Trials
Natalizumab
alemtuzumab
Therapeutics

Keywords

  • Alemtuzumab
  • Daclizumab
  • Multiple sclerosis
  • Natalizumab
  • Rituximab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Monoclonal antibodies in treatment of multiple sclerosis. / Rommer, P. S.; Dudesek, A.; Stüve, O.; Zettl, U. K.

In: Clinical and Experimental Immunology, Vol. 175, No. 3, 03.2014, p. 373-384.

Research output: Contribution to journalArticle

Rommer, P. S. ; Dudesek, A. ; Stüve, O. ; Zettl, U. K. / Monoclonal antibodies in treatment of multiple sclerosis. In: Clinical and Experimental Immunology. 2014 ; Vol. 175, No. 3. pp. 373-384.
@article{9e2c60d7c38a4f77a2ebcc79f1422d84,
title = "Monoclonal antibodies in treatment of multiple sclerosis",
abstract = "Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.",
keywords = "Alemtuzumab, Daclizumab, Multiple sclerosis, Natalizumab, Rituximab",
author = "Rommer, {P. S.} and A. Dudesek and O. St{\"u}ve and Zettl, {U. K.}",
year = "2014",
month = "3",
doi = "10.1111/cei.12197",
language = "English (US)",
volume = "175",
pages = "373--384",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Monoclonal antibodies in treatment of multiple sclerosis

AU - Rommer, P. S.

AU - Dudesek, A.

AU - Stüve, O.

AU - Zettl, U. K.

PY - 2014/3

Y1 - 2014/3

N2 - Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.

AB - Summary: Monoclonal antibodies (mAbs) are used as therapeutics in a number of disciplines in medicine, such as oncology, rheumatology, gastroenterology, dermatology and transplant rejection prevention. Since the introduction and reintroduction of the anti-alpha4-integrin mAb natalizumab in 2004 and 2006, mAbs have gained relevance in the treatment of multiple sclerosis (MS). At present, numerous mAbs have been tested in clinical trials in relapsing-remitting MS, and in progressive forms of MS. One of the agents that might soon be approved for very active forms of relapsing-remitting MS is alemtuzumab, a humanized mAb against CD52. This review provides insights into clinical studies with the mAbs natalizumab, alemtuzumab, daclizumab, rituximab, ocrelizumab and ofatumumab.

KW - Alemtuzumab

KW - Daclizumab

KW - Multiple sclerosis

KW - Natalizumab

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84893352807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893352807&partnerID=8YFLogxK

U2 - 10.1111/cei.12197

DO - 10.1111/cei.12197

M3 - Article

VL - 175

SP - 373

EP - 384

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -